Lunai Bioworks (NASDAQ:LNAI) Stock Price Up 1.1% – What’s Next?

Lunai Bioworks Inc. (NASDAQ:LNAI) shares rose 1.1% during trading on Monday . The company traded as high as $0.3797 and last traded at $0.3749. Approximately 1,093,185 shares were traded during trading, a decline of 98% from the average daily volume of 54,833,528 shares. The stock had previously closed at $0.3709.

Wall Street Analysts Forecast Growth

LNAI has been the topic of a number of research analyst reports. Wall Street Zen downgraded Lunai Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lunai Bioworks currently has an average rating of “Sell”.

Lunai Bioworks Stock Down 12.3%

The stock has a 50-day simple moving average of $0.46. The stock has a market cap of $7.18 million, a P/E ratio of 5.90 and a beta of 0.51.

Lunai Bioworks (NASDAQ:LNAI) last posted its earnings results on Tuesday, February 17th. The company reported ($0.08) EPS for the quarter.

Hedge Funds Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is currently owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.